Cancer treatment combining lymphodepleting agent with CTLs and cytokines

US7993638B2 · kind B2 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Zeling Cai · San Diego, US
• Ann Moriarty · Poway, US
• Per A. Peterson · Washington, US
• Jon Richards · San Francisco, US

Key dates

• Filing date: Feb 23, 2007
• Grant date: Aug 9, 2011
• Expiry date: Apr 9, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2239/57
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In a cancer treatment combining cell therapy with chemotherapy, autologous CD8+ T cells are obtained from a patient, activated ex vivo by contacting them with xenogenic antigen presenting cells loaded with selected peptide antigen, thereby generating antigen-specific activated cytotoxic T lymphocytes. Such activated CTLs are administered to the patient in conjunction with a lymphodepletion and CTL maintenance regimen comprising a non-myeloblative but lymphdepleting agent, such as cladribine or denileukin diftitox, and interleukin-2 and interferon-α-2b stimulatory cytokines.